Lupin’s US subsidiary launches Authorized Generic for Celebrex Capsules

11 Dec 2014 Evaluate

Pharma Major Lupin’s US subsidiary, Lupin Pharmaceuticals Inc has launched the authorized generic for G.D. Searle LLC’s (a subsidiary of Pfizer Inc)’ Celebrex Capsules (Celebrex) , which are available in 50 mg, 100 mg, 200 mg and 400 mg strengths. Lupin had earlier signed a licensing agreement with Pfizer Inc for Celebrex.

Celebrex Capsules had annual U.S sales of $ 2.54 billion, according to IMS MAT September, 2014.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin Share Price

1587.90 10.25 (0.65%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.